Allogene Therapeutics Inc (NYSE:ALLO) Q1 2019 Earnings Conference Call Transcript
May 07, 2019 • 08:30 am ET
Good morning, ladies and gentlemen. Thank you for standing by and welcome to Allogene Therapeutics First Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.
(Operator Instructions) Please be aware that today's conference is being recorded.
I would now like to turn the conference over to Ms. Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and good morning. Before market opened today, Allogene issued a press release that provides the corporate update and financial results for the quarter ending March 31, 2019. The press release is available on our website at www.allogene.com. We remind listeners that today's call is being webcast on our website and will be available for replay. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; and Dr. Eric Schmidt, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, regulatory filings, future research and development efforts and manufacturing capabilities, among other thing. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.
These and other risks are described in our periodic filings made with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2018, as well as our upcoming Form 10-Q for the quarter ended March 31, 2019. You are cautioned not to place undue reliance on these forward-looking statements and the Company disclaims any obligation to update such statements.
I'll now turn the call over to Dr. David Chang.
Thank you, Christine. Good morning and thank you all for joining us today. It's now officially one year since the launch of Allogene. On a personal note, this also marks my five years in the field of CAR T. It has been a distinct pleasure to play a role in advancing the exciting field of engineered cell therapy first at type with autologous and now at Allogene with allogeneic approach. And yes, I believe we are still in early days of unlocking the full power and versatility of cell therapy.
Our singular focus from day one at Allogene was how we could accelerate the development of AlloCAR T therapy to enable an off-the-shelf CAR T therapy that could allow more timely treatment to patient in need. Our goal of revolutionizing the cell therapy landscape represents an ambitious challenge, but it is one that I am very proud our team has vigorously embraced across every function. In May 2018, we started out with approximately 40 employees who joined us from Pfizer, where they had been working diligently for years on this pursuit.
We are now just over 150 people, all dedicated to the goal